1374573-70-2 Usage
Derivative of acetic acid
2-(2-methyl-4-(1H-tetrazol-1-yl)phenyl)acetic acid is derived from acetic acid, which means it has a similar structure and properties to acetic acid.
Tetrazole ring
The compound contains a tetrazole ring, which is a five-membered heterocyclic compound containing four nitrogen atoms. The presence of this ring makes the compound useful in targeting specific receptors within the body.
Pharmaceutical intermediate
2-(2-methyl-4-(1H-tetrazol-1-yl)phenyl)acetic acid is commonly used as a pharmaceutical intermediate in the synthesis of various drugs.
Active ingredient in NSAIDs
The compound is used as an active ingredient in the production of nonsteroidal anti-inflammatory drugs (NSAIDs) such as etoricoxib and parecoxib.
Anti-inflammatory and analgesic properties
2-(2-methyl-4-(1H-tetrazol-1-yl)phenyl)acetic acid is also known for its potential anti-inflammatory and analgesic properties, which can be useful in the treatment of pain and inflammation.
Check Digit Verification of cas no
The CAS Registry Mumber 1374573-70-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,7,4,5,7 and 3 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1374573-70:
(9*1)+(8*3)+(7*7)+(6*4)+(5*5)+(4*7)+(3*3)+(2*7)+(1*0)=182
182 % 10 = 2
So 1374573-70-2 is a valid CAS Registry Number.
1374573-70-2Relevant academic research and scientific papers
INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
Paragraph 0099; 0100, (2016/09/26)
no abstract published
INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
Page/Page column 33, (2013/03/28)
This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kirl.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure
